FARMINGTON HILLS, Mich., May 11, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations by Mina Sooch, Founder and CEO, at the New Pathways in Retinal Diseases Panel at Retina World Congress (RWC) on May 12, 2022 and at H.C. Wainwright Global Investment Conference on May 24, 2022. Dr. David Lally will also be presenting masked safety data from Phase 2b APX3330 trial at RWC and Clinical Trials at the Summit on May 21, 2022.
Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference
Globe Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Amazon%20-%20Image%20by%20bluestork%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_logo%20and%20website-by%20Mojahid%20Mottakin%20via%20Shutterstock.jpg)
/Salesforce%20Inc%20HQ%20building-by%20JHVEPhoto%20via%20Shutterstock.jpg)
